Affymetrix Launches New Publication for Microarray Research; Website Features Articles on All Aspects of Microarray-Based Experiments.SANTA CLARA Santa Clara, city, Cuba Santa Clara (sän`tä klä`rä), city (1994 est. pop. 217,000), capital of Villa Clara prov., central Cuba. , Calif. -- Affymetrix Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :AFFX) announced today the launch of the Affymetrix UserForum, an online magazine featuring weekly updates on new technology, analyses, services, and training. The magazine will help scientists perform fast and successful GeneChip(R) microarray experiments. The UserForum provides an interactive community where Affymetrix customers can learn about new products and services, explore emerging applications, and share research challenges and success stories. The website offers feature articles, video interviews, and live web talks with interactive question-and-answer sessions. Topics covered include software tools, third-party providers, and collaboration updates, such as the 500K Control Program. "Affymetrix microarray users will learn about the very latest tools and applications that can help them plan and perform their GeneChip-based research in the lab," said Bronwyn Barnett, managing editor of UserForum. "The UserForum focuses on the whole product solution from the initial study design to the final data analysis. The content will help accelerate discovery by enabling customers to quickly select the right tools and services for the job." UserForum is a sister publication to the Affymetrix Microarray Bulletin (AMB AMB Ambient AMB Ambassador AMB Amber AMB Ambulance AMB Associação Médica Brasileira (Brazil) AMB Ambulatory AMB Advanced Memory Buffer (FBDIMM control unit on DRAM) ), a print and online magazine featuring interviews with scientists discussing their most recent discoveries based on microarray research. To visit the Affymetrix UserForum and to register for regular email updates, please visit: www.affymetrix.com/userforum/index.uf. Current UserForum articles and video interviews include: Collaboration to Create Control Cohort Databases for Affymetrix 500K Human Mapping Array Set Affymetrix is collaborating with researchers at the National Genome Research Genome Research is the title of a peer-reviewed scientific journal published by Cold Spring Harbor Laboratory Press. The focus of the journal is on genome-wide studies in any organism, including single gene studies that are placed in a genomic context. Network in Germany, GlaxoSmithKline, Erasmus MC The Erasmus MC (medical center) is the university hospital of the city of Rotterdam. It is affiliated with the Erasmus University. Special units include:
To watch this UserForum video, please visit: www.affymetrix.com/userforum/news/collaborations/schreiber.uf The Broad Institute's Mark Daly Mark Daly (born 12 March, 1973) is an Irish politician and member of the 23rd Seanad Éireann for Fianna Fáil on the Administrative Panel. From Kenmare, County Kerry, Daly is an auctioneer. External links
Mark Daly, Ph.D., and his team at the Broad Institute have developed a new software program, called Haploview, for analyzing linkage disequilibrium linkage disequilibrium n. The nonrandom association between two or more alleles such that certain combinations of alleles are more likely to occur together on a chromosome than other combinations of alleles. and haplotype haplotype /hap·lo·type/ (-tip) the group of alleles of linked genes, e.g., the HLA complex, contributed by either parent; the haploid genetic constitution contributed by either parent. hap·lo·type n. patterns in genotype data sets comprising up to tens of thousands of SNPs in thousands of individuals. To watch this UserForum video, please visit: www.affymetrix.com/userforum/analysis/statistics/daly1.uf Duke and Affymetrix Sign Five-Year Translational Medicine translational medicine Molecular medicine The constellation of activities which seek to translate the science of gene discovery, gene transfer, and functional genomics into gene-targeted therapies Agreement Duke's Joe Nevins and Geoff Ginsburg outline their formula for translational medicine success. To read this UserForum article, please visit: www.affymetrix.com/userforum/news/collaborations/duke.uf About AMB AMB is an online and print magazine published by Affymetrix that highlights leading microarray research and diagnostic development from around the world. AMB features interviews by and for scientists, statisticians Statisticians or people who made notable contributions to the theories of statistics, or related aspects of probability, or machine learning: A to E
About Affymetrix Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's Web site at www.Affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: uncertainties relating to the success of the UserForum magazine and publication initiatives discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. ; uncertainties relating to technological approaches, manufacturing (including risks related to the Company's ability to achieve hoped-for manufacturing yields for certain array products, including the ability to identify and resolve manufacturing problems), product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other risk factors are discussed in Affymetrix' Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion